The new direction in multiple myeloma blood tests.

EasyM is a liquid biopsy for minimal residual disease (MRD) monitoring in Multiple Myeloma. Earlier relapse detection. Better prognosis.

Sign up to follow our progress with bringing EasyM to the Myeloma community.

Click below for more use case information.

For Clinicians
For Patients
For Pharma

How it works.

How it works.

What it is exactly.

What it is exactly.

EasyMTM is a truly personalized, precise monitoring test for patients with Multiple Myeloma (MM) that is non-invasive and highly sensitive. It relies on sequencing the patients’ unique M-protein (a biomarker for MM), and then quantifying the change in M-protein levels over time. It is sensitive enough to detect Multiple Myeloma relapse 10 months earlier than traditional tests. Applied on peripheral blood, the test can be readily performed as frequently as needed, providing each patient with better routine monitoring than available conventional testing.

EasyM is a truly personalized, precise monitoring test for patients with Multiple Myeloma (MM) that is non-invasive and highly sensitive. It relies on sequencing the patients’ unique M-protein (a biomarker for MM), and then quantifying the change in M-protein levels over time. It is sensitive enough to detect Multiple Myeloma relapse 10 months earlier than traditional tests. Applied on peripheral blood, the test can be readily performed as frequently as needed providing each patient with better routine monitoring than available conventional testing.

Higher Sensitivity

By leveraging the power of our proven de novo antibody sequencing platform, our test can achieve high sensitivity at detecting Multiple Myeloma relapse from complete remission (CR) by 10 months earlier than conventional tests. This method also overcomes non-specificity and false positivity shortcomings associated with other tests.

Non-invasive Procedure

Frequent monitoring will finally be possible with our non-invasive blood-based test. Patients will not require bone marrow aspirations for EasyMTM to receive insight into their disease state. With only a small amount of blood, we will be able to monitor the disease status as frequently as needed with higher certainty, convenience, and comfort.

Truly Personalized

EasyMTM will monitor the M-protein biomarker unique to each patient providing real-time data throughout a patient’s clinical history. Other tests such as SPEP and IFE simply detect the presence of the abundant aberrant antibody (M-protein). Because EasyMTM tracks the unique sequence, it is not confounded by treatments that use antibody therapeutics.

EasyM versus comparable methods.

Parameter / MethodEasyMSPEPIFENGS
Sensitivity************
Specificity****************
Non-invasive****************
Relapse Detection***********

Explore our trial data

For Pharma / Biotech.

Learn how EasyM can be used for MM monitoring in a clinical trial for your therapy.

Learn how EasyM can be used for MM monitoring in a clinical trial for your therapy.

For Clinicians.

Learn how we can collaborate along the journey to bringing a Multiple Myeloma blood test to your patients.

Learn how we can collaborate along the journey to bringing a Multiple Myeloma blood test to your patients.

For Patients.

Explore our vision for Multiple Myeloma blood tests, follow our progress and see how you can advocate for your needs.

Explore our vision for Multiple Myeloma blood tests, follow our progress and see how you can advocate for your needs.

FAQs.

What are multiple myeloma symptoms and causes?

Multiple Myeloma (MM) is a type of cancer characterized by the accumulation of plasma cells in the bone marrow; it is often accompanied by CRAB features (hypercalcemia, renal insufficiency, anemia, and bone lesions). The causes are not fully understood.

There are multiple tests available. Some tests, such as SPEP and IFE are based on the detection of the abnormal antibody (called M-protein) in a patient’s serum. Other tests, such as MFC and NGS detect cancerous plasma cells in the bone marrow.

M-protein spike indicates the presence of abnormal antibodies produced by the plasma cells. Combined with other signs and symptoms, the finding of M-spike can be used as a tool to diagnose and monitor multiple myeloma.

Yes, a blood test that specifically measures M-protein can be used to detect and monitor Multiple Myeloma.

It is a test that measures M-protein in patient’s serum or plasma.

M-protein is an abnormal antibody that is produced by the multiplied plasma cells. M-protein is not present in normal serum. At the time of multiple myeloma diagnosis, the M-protein concentration in serum is typically higher than 30 g/L.

Minimal residual disease is a measure of depth of response to treatment. It has become an important parameter in assessing the disease burden in multiple myeloma. MRD status has been correlated to progression-free survival and overall survival in the clinic.

No, EasyM only requires a small drop of blood.

Yes, EasyM can be used to detect Bence Jones protein in urine. However, at the moment, EasyM has been only validated for M-protein detection in serum.

SPEP is a technique used to detect and quantify M-protein based on the separation of serum proteins on the gel. SPEP is non-invasive, inexpensive, widely available and appropriate for routine use. However, it is not appropriate for MRD detection due to its low sensitivity.

Similar to SPEP, IFE is an electrophoretic technique used to detect and characterize M-protein in a patient’s serum. Although it is more sensitive than SPEP, it is not appropriate for MRD detection.

FISH is a specialized method to detect gene mutations in plasma cells. The test is done to obtain prognostic information and to select the optimal treatment. The test requires a bone marrow sample.

Multiparametric flow cytometry (MFC) and next generation sequencing (NGS) are used to monitor the MRD. These methods estimate the myeloma tumor burden by the quantification of cell-based parameters, such as the expression of specific cell surface markers (MFC) or Ig gene rearrangements (NGS), detecting as few as 1 tumor cell in 1,000,000 nucleated cells. However, these methods are costly, require painful bone marrow aspiration and occasionally result in false negative readings.

sFLCs are immunoglobulin light chains that are not paired with heavy chains. sFLCs are present in serum of healthy individuals, but are increased in some pathological conditions, including Multiple Myeloma.